GEN

AAV in Action: Setting the Gold Standard in Viral Gene Delivery

When discussing challenges in gene therapy, delivery of the genetic payload is always at the top of the list. Whether discussing viral or nonviral gene delivery, challenges are present in every aspect ...
Business Wire

Latus Bio Unveils AAV-Ep+ Capsid Variant Capable of Unprecedented Protein Production in the Brain

PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...
The American Journal of Managed Care

CNS-Directed AAV Gene Therapy: Immune Dynamics and Clinical Implications

CNS-directed AAV gene therapy shows milder immune responses compared to systemic administration, reducing peripheral immune activation and systemic toxicities. Direct CNS delivery can bypass ...
Business Wire

JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today ...
GEN

Improved Methods for Characterization of AAV-Based Gene Therapies

Analyzing the purity of adeno-associated virus (AAV)-based gene therapy products requires effective methods for detecting host proteins, DNA, and incomplete viral particles in samples. It is a ...